Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Aug. 15, 2022 (GLOBE NEWSWIRE) —   Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused